NCT00034203
Completed
Phase 2
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
ConditionsRheumatoid Arthritis
Drugsefalizumab
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Rheumatoid Arthritis
- Sponsor
- XOMA (US) LLC
- Locations
- 48
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (48)
Loading locations...
Similar Trials
Completed
Phase 1
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic ArthritisPsoriatic ArthritisNCT00051662XOMA (US) LLC45
Completed
Phase 1
Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV InfectionHIV InfectionsNCT02591420National Institute of Allergy and Infectious Diseases (NIAID)24
Completed
Phase 1
Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult ParticipantsHIV InfectionsNCT03735849National Institute of Allergy and Infectious Diseases (NIAID)28
Withdrawn
Phase 2
A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19COVID-19NCT04770467Brii Biosciences, Inc.
Completed
Phase 2
Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV InfectionHIV InfectionsNCT02664415National Institute of Allergy and Infectious Diseases (NIAID)23